Chiasma Inc. | Mutual Funds
Mutual Funds that own Chiasma Inc.
Fidelity Select Biotechnology Portfolio
1,553,299
6.37%
0
0.04%
07/31/2018
Fidelity OTC Portfolio
779,500
3.2%
0
0.01%
07/31/2018
Fidelity Advisor Biotechnology Fund
331,092
1.36%
-6,100
0.03%
07/31/2018
Bridgeway Ultra Small Company Market Fund
172,389
0.71%
0
0.09%
12/31/2017
Vanguard Total Stock Market Index Fund
161,721
0.66%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
58,188
0.24%
0
0%
07/31/2018
iShares Micro Cap ETF
54,655
0.22%
0
0.01%
09/06/2018
DFA US Core Equity 2 Portfolio
37,057
0.15%
0
0%
04/30/2018
Fidelity Spartan Extended Market Index Fund
30,058
0.12%
0
0%
07/31/2018
DFA US Core Equity 1 Portfolio
11,524
0.05%
0
0%
04/30/2018
| Address |
460 Totten Pond Road
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.chiasmapharma.com |
| Updated |
07/08/2019 |
| Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The company's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications. |
